Close

Minerva Neurosciences (NERV) Reports Six-Month Data from Phase IIb Trial of MIN-10 in Schizophrenia

October 26, 2016 8:36 AM EDT Send to a Friend
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login